Isaac-Coss Giovannie, Post Zoë, Kakarla Megahna, Johnsky Lily, Sakuraba Atsushi, Miller Ira, Shriram Jakate M, Frasca Joseph
Rush University Medical Center, Chicago, IL.
Infirmary Health, Mobile, AL.
ACG Case Rep J. 2025 Aug 11;12(8):e01795. doi: 10.14309/crj.0000000000001795. eCollection 2025 Aug.
This case report describes the novel use of infliximab as maintenance therapy for both Crohn disease and idiopathic retroperitoneal fibrosis in a patient with concurrent disease. A 34-year-old man with Crohn disease developed a pelvic mass and hydroureteronephrosis, leading to an idiopathic retroperitoneal fibrosis diagnosis. Given shared inflammatory pathways, he was treated with prednisone followed by infliximab. Post-treatment imaging showed mass reduction and hydronephrosis improvement. After 1 year, he remains stable. This case highlights infliximab's potential in managing both conditions, presenting a unique therapeutic approach. Further studies are needed to evaluate its broader application in dual pathology.
本病例报告描述了英夫利昔单抗在一名同时患有克罗恩病和特发性腹膜后纤维化的患者中作为维持治疗药物的新用途。一名患有克罗恩病的34岁男性出现盆腔肿块和肾盂积水，从而被诊断为特发性腹膜后纤维化。鉴于存在共同的炎症途径，他先接受了泼尼松治疗，随后使用英夫利昔单抗进行治疗。治疗后的影像学检查显示肿块缩小，肾积水有所改善。1年后，他的病情保持稳定。该病例突出了英夫利昔单抗在治疗这两种病症方面的潜力，展现了一种独特的治疗方法。需要进一步研究以评估其在双重病理中的更广泛应用。
